Twenty-nine evaluable patients with anthracycline-resistant metastatic bone or soft tissue sarcomas were treated with chlorozotocin, 150 mg/m2 every 6 weeks. Four patients (14%) achieved partial responses. The most severe toxicity was usually thrombocytopenia (which occurred in 31% of patients). Chl
A phase II study of chlorozotocin in metastatic malignant melanoma
โ Scribed by Daniel F. Hoth; Philip S. Schein; Stanley Winokur; Paul V. Woolley; Kay Robichaud; Richard B. Binder; Frederick P. Smith
- Publisher
- John Wiley and Sons
- Year
- 1980
- Tongue
- English
- Weight
- 713 KB
- Volume
- 46
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Abstract Trimetrexate glucuronate, a nonclassical antifolate, was administered to 14 patients with recurrent and progressive metastatic malignant melanoma. Thirteen patients were evaluable for response and toxicity. Five patients had received prior treatment consisting of immunotherapy (one pati
Eighteen patients with surgically incurable metastatic malignant melanoma were treated with a mixture of irradiated (15,000 rads) autologous tumors cells (1-2 X 10(8)) and BCG (Glaxo, 2-4.5 X 10(6) organisms), which was injected intradermally (in five divided doses) every 2 weeks (X5). Four of 18 (2